Immunocore Holdings Ltd (IMCR)

Official site

HEALTHCARE • BIOTECHNOLOGY • NASDAQ

$30.99

+2.59 (+9.12%)

Market Cap: $1.46B

Last updated: Nov 06, 2026 at 4:10 PM ET

Earnings

Performance (10Y)

Beat Rate

57%(13/23)

Avg Surprise

-7811.12%

Upcoming Estimates

Period ending Dec 31, 2026

EPS Consensus$0.32

Range$-0.09 - $0.59

11 analysts

Revenue Consensus

$122M

Range$111M - $137M

13 analysts

Last 12 of 31 reported quarters and 1 upcoming estimate

Period	Reported	Est.	Range	Surprise	B/M	Analysts	Revisions	YoY
Dec 31, 2026Dec 26EST	-	$0.32	$-0.09 - $0.59	-	-	11	-	-
Sep 30, 2026Sep 26 Reported Nov 5, 2026Reported Nov 5	$N/A	$-0.12	$-0.26 - $0.00	N/A	Beat	12	1 9 30d	-
Jun 30, 2026Jun 26 Reported Aug 6, 2026Reported Aug 6	$-0.02	$-0.01	$-0.18 - $0.32	-100.00%	Miss	11	2 0 30d	+90.0%
Mar 31, 2026Mar 26 Reported May 6, 2026Reported May 6	$0.25	$-0.26	$-0.42 - $-0.10	+196.15%	Beat	12	1 7 30d	+150.0%
Dec 31, 2025Dec 25 Reported Feb 25, 2026Reported Feb 25	$-0.60	$-0.20	$-0.52 - $0.00	-204.57%	Miss	11	1 1 30d	-61.6%
Sep 30, 2025Sep 25 Reported Nov 6, 2025Reported Nov 6	$-0.00	N/A	-	+98.54%	Beat	13	2 1 30d	-102.1%
Jun 30, 2025Jun 25 Reported Aug 7, 2025Reported Aug 7	$-0.20	$-0.21	$-0.56 - $-0.01	+4.76%	Beat	12	2 1 30d	+13.0%
Mar 31, 2025Mar 25 Reported May 7, 2025Reported May 7	$0.10	N/A	-	+125.00%	Beat	12	0 2 30d	+120.4%
Dec 31, 2024Dec 24 Reported Feb 26, 2025Reported Feb 26	$-0.37	$-0.16	$-0.72 - $0.23	-133.00%	Miss	12	1 12 30d	+98.8%
Sep 30, 2024Sep 24 Reported Nov 6, 2024Reported Nov 6	$0.17	$-0.34	-	+150.00%	Beat	15	No revisions (30d)	+240.0%
Jun 30, 2024Jun 24 Reported Aug 8, 2024Reported Aug 8	$-0.23	N/A	-	+55.77%	Beat	17	1 0 30d	+37.8%
Mar 31, 2024Mar 24 Reported May 8, 2024Reported May 8	$-0.49	$-0.38	$-0.51 - $-0.10	-28.95%	Miss	17	1 0 30d	-11.4%
Dec 31, 2023Dec 23 Reported Feb 28, 2024Reported Feb 28	$-32.22	$-21.74	$-22.00 - $-21.52	-48.21%	Miss	16	2 0 30d	+40.3%

Key Metrics

Valuation
P/E Ratio	-82.97	EV/EBITDA	90.74x
Price/FCF	-25.26x	FCF Yield	-3.96%
Profitability
Profit Margin	-4.20%	Operating Margin	-2.58%
ROE	-4.47%	ROIC	1.02%
Financial Health
Debt/Equity	0.94x	Interest Coverage	1.12x
Current Ratio	4.47x	Quick Ratio	4.44x
Trading Statistics
Beta	0.81	Avg Volume	544.88K
52-Week High	$40.71	52-Week Low	$27.50

Technical Indicators Dashboard

Moving Averages

SMA 10$30.61

SMA 20$30.39

SMA 50$31.64

SMA 200$31.66

EMA 10$30.26

EMA 20$30.49

EMA 50$31.29

EMA 200$32.00

MACD

Line: -0.33Signal: -0.28Hist: -0.05

ADX

ADX: 18.2+DI: 21.3-DI: 23.5

Aroon & PSAR

Aroon Up52.0

Aroon Down32.0

PSAR$32.92

Bollinger Bands

Upper Band$33.33

Lower Band$27.45

%B Position1933%(Upper)

Band Width0.60

RSI (14-Day)

Neutral

51.5

Momentum Oscillators

Stoch %K23.4

Stoch %D21.6

Williams %R-47.3

ROC (10d)0.0%

Momentum0.01

CCI (20d)4.8

MFI (14d)58.5

Volatility Measures

ATR (14d)$1.49(4.8%)

StdDev (20d)1.47

Hist Vol60.6%(High)

Volume Flow

VWAP$30.47

OBV-1.6M

AD Line-5.6M

CMF (20d)-0.117

Volume Metrics

Avg Vol (20d)555.5K

Vol Ratio2.7x(High)

VWMA (20d)$30.49

Pivot Points

R3$30.54

R2$30.00

R1$29.20

Pivot Point$28.66

S1$27.86

S2$27.32

S3$26.52

Advanced Oscillators

TSI-7.16

Ultimate Osc41.5

KST-2.13

Financial Data

Quarter	Jun 2026	Mar 2026	Dec 2025	Sep 2025	Jun 2025	Mar 2025	Dec 2024	Sep 2024	Jun 2024	Mar 2024	Dec 2023	Sep 2023
Total Revenue	$115.93M	$106.68M	$77.43M	$103.69M	$97.96M	$93.88M	$84.05M	$80.25M	$75.40M	$70.50M	$56.01M	$53.56M
Cost of Revenue	$1.09M	$434,000	$2.62M	$513,000	$1.04M	$831,000	$330,000	$448,000	$1.71M	$246,000	$159,647	$1.65M
Gross Profit	$114.84M	$106.24M	$74.81M	$103.18M	$96.92M	$93.05M	$83.72M	$79.80M	$73.69M	$70.26M	$55.85M	$51.91M

Operating Expenses	$117.83M	$98.96M	$89.40M	$110.35M	$111.80M	$96.67M	$103.17M	$88.30M	$89.71M	$96.75M	$69.46M	$62.31M
R&D	$73.94M	$61.11M	$58.41M	$70.57M	$69.01M	$56.47M	$60.85M	$52.77M	$51.07M	$57.46M	$36.37M	$32.95M
SG&A	$43.89M	$37.85M	$42.65M	$39.78M	$42.79M	$40.20M	$49.50M	$23.91M	$25.59M	$39.29M	$47.00M	$23.37M
Operating Income	$-2,996,000	$7.28M	$-14,592,758	$-7,171,000	$-14,875,000	$-3,616,000	$-19,452,000	$-8,502,000	$-16,017,000	$-26,490,000	$-13,611,559	$-10,399,132

Interest Income	$3.58M	$3.42M	$3.91M	$4.12M	$4.27M	$4.18M	$5.17M	$5.96M	$6.24M	$8.25M	$7.94M	$4.09M
Interest Expense	$3.06M	$2.31M	$3.05M	$3.04M	$3.08M	$3.02M	$6.97M	$3.78M	$3.76M	$3.24M	$1.04M	$1.09M
Income Before Tax	$-514,000	$13.27M	$-11,704,739	$304,000	$-9,694,000	$6.08M	$-24,821,000	$6.09M	$-10,130,000	$-24,079,000	$-20,467,628	$1.83M
Income Tax Expense	$294,000	$300,495	$10.57M	$-481,000	$606,000	$1.06M	$-1,050,000	$-2,643,000	$1.49M	$357,000	$-4,718,386	$-149,792

Net Income	$-808,000	$12.97M	$-22,277,097	$785,000	$-10,300,000	$5.02M	$-23,771,000	$8.74M	$-11,616,000	$-24,436,000	$-15,749,241	$1.98M

EBITDA	$3.57M	$16.53M	$-7,817,739	$4.14M	$-6,399,000	$9.96M	$-15,274,000	$10.91M	$-5,374,000	$-19,829,000	$-19,423,531	$4.28M
EBIT	$2.55M	$15.58M	$-8,651,739	$3.35M	$-7,179,000	$9.11M	$-16,440,000	$9.87M	$-6,366,000	$-20,840,000	$-24,665,672	$2.92M

* Some calculated fields are derived from available data when not provided by source

Related GNG Research

No research available

Be the first to write about IMCR

Government Contracts

Gov Obligations (TTM)

-$888

Gov Obligations / Revenue

0.0%

Obligations YoY

N/A

Active Awards

New Awards (TTM)

Avg Remaining Term

N/A

Federal contract obligations are bookings recorded by the awarding agency, not recognized revenue. They can exceed 100% of revenue and can be negative when contracts are de-obligated. Source: USAspending.gov prime awards, data through Sep 30, 2026.

News

Immunocore 3Q 2026: Revenue $102.22M, EPS ($0.28) — 10-Q Summary

Immunocore (IMCR) reported a 1.4% year-over-year decline in third-quarter revenue to $102.22 million, and its net loss significantly widened to $14.22 million...

TradingView•Nov 6, 2026 9:30 AM ET11/6/26•Somewhat-Bearish

Immunocore Reports Q3 2026 Revenue of $102.2 Million and $14.2 Million Net Loss

Immunocore reported its third-quarter 2026 financial results, with revenue declining slightly to $102.2 million from $103.7 million in Q3 2025, and a net loss of $14.2 million. Despite the quarterly dip...

TradingView•Nov 6, 2026 9:30 AM ET11/6/26•Neutral

Form 8K Immunocore Holdings plc For: 6 November By Investing.com

This article announces that Immunocore Holdings plc has filed a Form 8K on November 6th. The filing is available through Investing.com...

Investing.com UK•Nov 6, 2026 9:30 AM ET11/6/26•Neutral

Revenue fell 1.4% at Immunocore (IMCR), while its quarterly loss widened.

Immunocore Holdings plc (IMCR) reported a 1.4% decrease in third-quarter revenue to $102.2 million, while its net loss for the quarter widened significantly to $14.2 million from $177,000 in the prior year. Despite...

Stock Titan•Nov 6, 2026 9:30 AM ET11/6/26•Somewhat-Bearish

Immunocore Holdings plc (IMCR) Seasonal returns chart - Yahoo Finance

The article displays the seasonal returns chart for Immunocore Holdings plc (IMCR) on Yahoo Finance. It provides the average monthly price return for the company from 2021 to 2026...

Yahoo Finance Singapore•Nov 4, 2026 9:41 PM ET11/4/26•Neutral

IMCR Valuation and Fair Value

P/E: -83.0x
Forward P/E: 21.9x
EV/EBITDA: 90.7x
P/FCF: -25.3x
P/B: 3.8x

See GNG's fair value

IMCR Profitability: Margins, ROIC and FCF

Gross margin: 98.8%
Operating margin: -2.6%
Net margin: -4.2%
ROIC: 1.0%
ROE: -4.5%
FCF margin: -15.5%
FCF yield: -4.0%

IMCR Competitors

Company	Ticker
Nuvation Bio Inc	NUVB
Pacira BioSciences, Inc.	PCRX
Uniqure NV	QURE
U.S. Physical Therapy, Inc.	USPH
Tyra Biosciences Inc	TYRA
Phibro Animal Health Corporation	PAHC
Precigen Inc	PGEN
UroGen Pharma Ltd	URGN

Sector: Healthcare

IMCR Analyst Ratings

Consensus: Buy
Analysts: 13
Strong Buy: 2
Buy: 7
Hold: 4
Sell: 0
Strong Sell: 0

IMCR Bull Case vs Bear Case

Bull case

IMCR grew quarterly revenue 18.3% year over year.
69.2% of IMCR's analyst ratings are Buy or Strong Buy.

Bear case

IMCR has a -4.2% net profit margin.

IMCR Earnings: Beat Rate and Next Report

Beat rate: 5 of 8 quarters (62.5%)
Average surprise: 17.1%
EPS estimate (fiscal period ending Dec 31, 2026): $0.32

IMCR Earnings Date

IMCR reports Feb 23, 2027, after the close. The date is estimated.

IMCR Earnings Call

The latest IMCR earnings call transcript on file is labeled 2026Q2.

Read the 2026Q2 transcript

IMCR ETF Holders

GNG tracks 3 ETFs that hold IMCR. The largest weights:

abrdn Healthcare Investors (HQH), 0.18% of the fund
iShares Biotechnology ETF (IBB), 0.10% of the fund
BlackRock Health Sciences Trust (BME), 0.09% of the fund

Open the ETF Stock Exposure tool for IMCR

Frequently Asked Questions About IMCR

When does IMCR report earnings?

Immunocore Holdings Ltd (IMCR) is expected to report earnings on Feb 23, 2027.

Does IMCR pay dividends?

Immunocore Holdings Ltd (IMCR) does not currently pay a regular dividend.

What is IMCR's market cap?

Immunocore Holdings Ltd (IMCR) has a market capitalization of $1.46B with a current stock price of $30.99.

Get full access to GNG Research

Create a free account to access portfolio tracking, advanced tools, and more.

Create Free Account Log In